Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Enanta's Pharmaceuticals Fiscal Fourth Quarter and Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of prepared remarks. Please be advised that this call is being recorded. I will now turn the conference over to your host, Ms. Jennifer Vieira, Investor Relations. Please go ahead. Thank you, Operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal fourth quarter and year-end 2023 financial results was issued this afternoon and is available on our website. Making formal remarks on today's call are Dr. Jay Lulli, President and Chief Executive Officer, and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer, and Dr. Tara Kiefer, our Senior Vice President of New Product Strategy and Development, will be available during the Q&A portion of the call. Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-K and other periodic reports filed with the SEC. Ananta does not undertake any obligation to update any forward-looking statements made during the call. With that, I'd now like to turn the call over to Dr. Jay Lulli, President and CEO. Jay? Thank you, Jennifer, and good afternoon, everyone. In fiscal 2023, Ananta took important steps leading to meaningful ...